IN2014MN01651A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01651A
IN2014MN01651A IN1651MUN2014A IN2014MN01651A IN 2014MN01651 A IN2014MN01651 A IN 2014MN01651A IN 1651MUN2014 A IN1651MUN2014 A IN 1651MUN2014A IN 2014MN01651 A IN2014MN01651 A IN 2014MN01651A
Authority
IN
India
Prior art keywords
group
amino
aldehyde groups
aliphatic
aldehyde
Prior art date
Application number
Inventor
Tomasz Ciach
Iga Wasiak
Original Assignee
Nanovelos Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovelos Sp Z O O filed Critical Nanovelos Sp Z O O
Publication of IN2014MN01651A publication Critical patent/IN2014MN01651A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B1/00—Preparatory treatment of cellulose for making derivatives thereof, e.g. pre-treatment, pre-soaking, activation
    • C08B1/08—Alkali cellulose
    • C08B1/10—Apparatus for the preparation of alkali cellulose
    • C08B1/12—Steeping devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
    • C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The process for the preparation of nanoparticles from polysaccharides and derivatives thereof by their specific partial oxidation to produce aldehyde groups and attach compounds with amino or other group with the R NH2 bond which react with aldehyde groups comprising oxidizing the polysaccharide or derivative thereof by a known method to obtain aldehyde groups until the oxidation degree of 0 1% to 80% of the sugar rings is obtained then adding at least one nanoparticle forming agent which after attachment of the aldehyde group exhibits hydrophobic properties selected from the group comprising: aliphatic or aromatic organic amines containing from 4 to 20 carbon atoms amides and hydrazides of aliphatic and aromatic organic acids containing from 4 to 20 carbon atoms hydrophobic amino acids phosphatidylethanolamine and at least one active substance containing at least one amino amido or hydrazide group to the solution of the oxidized polysaccharide in water or a mixture of water and an organic solvent carrying the reaction out at pH of the solution from 1 to 9 at the temperature of from 10 to 100°C wherein the total molar ratio of amino groups to aldehyde groups is from 20 to 0 5.
IN1651MUN2014 2012-03-14 2013-03-12 IN2014MN01651A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL398450A PL221351B1 (en) 2012-03-14 2012-03-14 Method for obtaining polysaccharide nanoparticles
PCT/PL2013/000030 WO2013137755A1 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles

Publications (1)

Publication Number Publication Date
IN2014MN01651A true IN2014MN01651A (en) 2015-05-29

Family

ID=48014274

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1651MUN2014 IN2014MN01651A (en) 2012-03-14 2013-03-12

Country Status (14)

Country Link
US (1) US10258579B2 (en)
EP (1) EP2825563B1 (en)
JP (1) JP6470169B2 (en)
CN (1) CN104169305B (en)
AU (1) AU2013232850B2 (en)
BR (1) BR112014022767B1 (en)
CA (1) CA2866682C (en)
ES (1) ES2780387T3 (en)
IL (1) IL234572A (en)
IN (1) IN2014MN01651A (en)
MX (1) MX369114B (en)
PL (1) PL221351B1 (en)
RU (1) RU2632019C2 (en)
WO (1) WO2013137755A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6640736B2 (en) * 2014-12-12 2020-02-05 日本化薬株式会社 Hyperbranched compounds bound with nucleic acid antimetabolites
DK3491092T3 (en) * 2016-08-01 2023-11-13 Integrity Bio Chemicals Llc BIOPOLYMERS FOR VOLATILE DUST CONTROL
US10736964B2 (en) * 2017-05-01 2020-08-11 China Medical University Immunomagnetic nanocapsule and kit for treating cancer
CN107446054B (en) * 2017-08-11 2021-05-18 武汉理工大学 A kind of biomass-based nanoparticle and its preparation method and application
PL424773A1 (en) * 2018-03-06 2019-09-09 Nanovelos Spółka Akcyjna Polysaccharide encapsulated anthracycline for use in the treatment of cancer
CN108553448A (en) * 2018-05-30 2018-09-21 江西师范大学 A kind of preparation method of the medicament slow release cellulose nano particle of pH responses
CN108676181B (en) * 2018-05-30 2022-05-17 江西师范大学 Method for preparing cellulose nanoparticles by dialdehyde-based cellulose
PL240772B1 (en) 2018-06-11 2022-06-06 Nanothea Spolka Akcyjna Method of producing polymer nanoparticles chelating radioactive isotopes for use in diagnostics and treatment
CN112353781B (en) * 2020-11-12 2022-08-19 云南开放大学 Preparation method of hollow nanosphere of drug carrier
CN112516310B (en) * 2020-12-11 2022-11-29 武汉理工大学 Preparation method and application of nano prodrug with response to tumor acid environment
CN112830979A (en) * 2021-01-15 2021-05-25 江南大学 A kind of modified xanthan gum and its preparation method and application
CN113800501B (en) * 2021-10-08 2023-04-18 山西大学 Preparation method and application of orange-red fluorescent carbon dots for detecting pH and arginine
WO2023092208A1 (en) * 2021-11-25 2023-06-01 Universidade Estadual De Campinas Method for producing a photocrosslinkable injectable polymeric solution, photocrosslinkable injectable polymeric solution and uses thereof
CN115463262B (en) * 2022-08-11 2024-06-04 南方医科大学第五附属医院 Hydrogel composite repair patch and preparation method and application thereof
CN117898426A (en) * 2023-12-05 2024-04-19 江苏蓝果临床营养科技有限公司 Nanoparticle for regulating intestinal dysfunction and preparation method thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU825542A1 (en) * 1979-04-04 1981-04-30 Inst Orch Chimii Aka Method of preparing polysuccharide n-derivatives
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4693912A (en) * 1985-02-28 1987-09-15 Technicon Instruments Corporation Lyophilization of reagent-coated particles
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
JPS62221637A (en) * 1986-03-24 1987-09-29 Green Cross Corp:The Production of carcinostatic agent-antibody complex
JPS62283101A (en) * 1986-05-30 1987-12-09 Green Cross Corp:The Production of composite of carcinostatic substance
JPS63264427A (en) * 1986-12-17 1988-11-01 Green Cross Corp:The Complex of carcinostatic substance
JPH01190636A (en) * 1988-01-22 1989-07-31 Green Cross Corp:The Composite of carcinostatic substance
EP0999222A1 (en) 1998-11-02 2000-05-10 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Carbohydrate oxidation products
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
IL153505A0 (en) 2000-06-29 2003-07-06 Daiichi Seiyaku Co Dds compound and process for the preparation thereof
DE10129369C1 (en) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Water soluble antibiotic in the form of a polysaccharide conjugate containing an aminosugar
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
DE10209821A1 (en) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
WO2003101425A2 (en) * 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
KR100578382B1 (en) * 2004-07-16 2006-05-11 나재운 Water Soluble Chitosan Nanoparticles for Carrier of Anticancer Agents
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1898881B1 (en) * 2005-05-27 2012-04-04 Royer Biomedical, INC. Bioresorbable polymer matrices and methods of making and using the same
WO2007023386A2 (en) 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
GB2436745B8 (en) * 2005-09-09 2019-03-13 Jae Woon Nah Method for enhancing the solubility of paclitaxel
EP1926498A2 (en) * 2005-09-22 2008-06-04 Hadasit Medical Research Services And Development Company Ltd. Dextran and arabinogalactan conjugates of therapeutically active compounds
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
JP5559190B2 (en) * 2008-11-19 2014-07-23 アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー Fibrous tissue sealant and method of use thereof
CZ302503B6 (en) * 2009-12-11 2011-06-22 Contipro C A.S. Process for preparing hyaluronic acid derivative oxidized in position 6 of polysaccharide glucosamine portion to aldehyde and modification process thereof
US20130178437A1 (en) 2010-07-09 2013-07-11 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
PL398450A1 (en) 2013-09-16
IL234572A (en) 2017-01-31
MX2014010979A (en) 2015-02-24
MX369114B (en) 2019-10-29
EP2825563B1 (en) 2020-02-05
RU2014133962A (en) 2016-03-20
PL221351B1 (en) 2016-03-31
BR112014022767A2 (en) 2017-10-03
WO2013137755A1 (en) 2013-09-19
AU2013232850A1 (en) 2014-09-11
RU2632019C2 (en) 2017-10-02
CN104169305A (en) 2014-11-26
JP2015514059A (en) 2015-05-18
CA2866682A1 (en) 2013-09-19
BR112014022767B1 (en) 2021-08-31
ES2780387T3 (en) 2020-08-25
US10258579B2 (en) 2019-04-16
US20150072946A1 (en) 2015-03-12
EP2825563A1 (en) 2015-01-21
JP6470169B2 (en) 2019-02-13
CN104169305B (en) 2016-07-27
CA2866682C (en) 2016-05-17
AU2013232850B2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
IN2014MN01651A (en)
JP6193499B2 (en) Method for producing N-acyl acidic amino acid or salt thereof and use thereof
CN102399304B (en) Chitosan quaternary amine salt gallate, synthetic method thereof and application thereof
AR088296A1 (en) RASAGILINE CITRAMIDE, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION
MX2019011095A (en) Adhesive composition and method for preparing same.
JO2928B1 (en) A method for the preparation of ferroquine with amine by convergent reduction
IN2015DN03205A (en)
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
EP2759547A4 (en) SUBSTITUTED GROUP CONTAINING AMINO OR ALKYLAMINO DERIVATIVES OF SUCCINIC ACID OF THE PLATINUM COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATIONS
BR112013005421A2 (en) "process for producing polyamides, and use of polyamides".
HUP0300761A2 (en) Process for the production of amorphous atorvastatin calcium
CN103694445B (en) A kind of preparation method of spray polyurea elastic material
ZA202103286B (en) Processes for preparing nitrosylated propanediols, compositions comprising the same, and medical uses thereof
EP2733134A3 (en) Alternative to tetrazene
UA104857C2 (en) Method for obtaining uranium dioxide with spherical and irregular grains
JP2013526577A5 (en)
FR2973370B1 (en) LOW COST PROCESS FOR THE PREPARATION OF O-ACETYLSALICYCLIC ACID AND BASIC AMINO ACID
BRPI1013091A2 (en) SUSPENSION COMPOSITION, AND METHOD FOR PREPARING A SUSPENSION COMPOSITION
BR112018069201A2 (en) enzymatic composition and method for the preparation of a liquid enzyme composition
RU2008138808A (en) METHOD FOR PRODUCING ORGANOPHILIC BENTONITE
KR101574441B1 (en) Process for Preparing N-Guanylurea Dinitramide(GUDN) from Metformin
RU2458930C1 (en) Method of producing humin-containing iron chelate
CN104003938B (en) Preparation method and application of 1-carboxyalkyl-4-nitroimidazole
CN106883318A (en) A kind of synthetic method of the metal complex of chitosan oligosaccharide containing ferro element
CN103951570A (en) Method for preparing DL-isoserine